Product Description
Glycopyrronium (Qbrexza) topical wipes are labeled for the treatment of hyperhidrosis. Glycopyrronium wipes contain a topically-dosed anticholinergic. When applied to the axillae, they reduce sweating in patients nine years and older with hyperhidrosis (Sourced from: https://www.aafp.org/afp/2019/0915/p372.html)
Mechanisms of Action: M1 Antagonist,M2 Antagonist,M3 Antagonist,M4 Antagonist,M5 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Guatemala, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Africa, Spain, Sweden, Thailand, Turkey, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 18
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Hyperhidrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2022-001476-33 | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-03-26 |
48% |
2025-07-09 |
Treatments |
| CQVM149C2201 | P2 |
Recruiting |
Asthma |
2027-07-30 |
12% |
2025-06-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| CQVM149C2201 | P2 |
Recruiting |
Asthma |
2025-05-31 |
2025-05-02 |
Treatments |
|
| GPBK-08/2018 | P2 |
Completed |
Hyperhidrosis |
2024-03-06 |
50% |
2024-04-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| Pharmacokinetics, pharmacodynamics, safety and tolerability of glycopyrronium (bromide) in children | P2 |
Active, not recruiting |
Asthma |
2023-12-25 |
12% |
2025-05-22 |
Treatments |
| CTR20243686 | P2 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-08-01 |
27% |
2025-02-15 |
Primary Completion Date|Primary Endpoints|Start Date |
| D5989C00001 THARROS | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2028-03-07 |
43% |
2025-05-02 |
|
| TRITON | P3 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2026-01-01 |
26% |
2025-01-16 |
Patient Enrollment|Primary Endpoints |
| D5985C00002 | P3 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2025-09-05 |
46% |
2025-05-02 |
Treatments |
| ATHLOS | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2025-08-24 |
47% |
2024-06-28 |
Primary Endpoints |
| D5985C00002 | P3 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2025-08-19 |
46% |
2025-06-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
| D5982C00008 | P3 |
Completed |
Asthma |
2025-03-19 |
2025-05-02 |
Treatments |
|
| D5982C00007 | P3 |
Completed |
Asthma |
2025-03-18 |
2025-05-02 |
Treatments |
|
| Anti-inflammatory effects of Glycopyrronium | P3 |
Active, not recruiting |
Asthma |
2022-07-02 |
2022-03-13 |
Treatments |
|
| JapicCTI-194818 | P3 |
Planned |
Hyperhidrosis |
2021-08-31 |
|||
| D598AC00001 | P1 |
Completed |
Asthma |
2025-06-01 |
23% |
2025-06-06 |
Primary Completion Date|Primary Endpoints |
| CTR20211136 | P3 |
Recruiting |
Asthma |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |